How does BNND's PS Ratio compare to its peers?

BNND is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (3.1x).

How does BNND's PS Ratio compare vs other companies in the GB Chemicals Industry?

BNND is expensive based on its Price-To-Sales Ratio (2.7x) compared to the UK Chemicals industry average (1.2x).

What is BNND's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate BNND's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of BNND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate BNND's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

BNND Stock Overview

Engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details

BNND fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 70.86% per year

Risk Analysis

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

BRAIN Biotech AG Competitors

Synthomer

LSE:SYNT

UK£259.1m

Treatt

LSE:TET

UK£309.2m

Iofina

AIM:IOF

UK£37.4m

Carclo

LSE:CAR

UK£18.9m

Price History & Performance

Summary of share price highs, lows and changes for BRAIN Biotech
Historical stock prices
Current Share Price	€5.86
52 Week High	€6.08
52 Week Low	€5.86
Beta	1.44
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-45.74%
5 Year Change	n/a
Change since IPO	-61.80%

Recent updates

Shareholder Returns

	BNND	GB Chemicals	GB Market
7D	0%	0.01%	-0.6%
1Y	n/a	-24.5%	3.1%

Return vs Industry: Insufficient data to determine how BNND performed against the UK Chemicals industry.

Return vs Market: Insufficient data to determine how BNND performed against the UK Market.

Price Volatility

Is BNND's price volatile compared to industry and market?
BNND volatility
BNND Average Weekly Movement	n/a
Chemicals Industry Average Movement	6.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: BNND has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BNND's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	312	Aryan Moelker	www.brain-biotech.com

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries.

BRAIN Biotech AG Fundamentals Summary

How do BRAIN Biotech's earnings and revenue compare to its market cap?
BNND fundamental statistics
Market cap	€130.21m
Earnings (TTM)	-€8.23m
Revenue (TTM)	€47.53m

2.7x

P/S Ratio

-15.8x

P/E Ratio

Is BNND overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BNND income statement (TTM)
Revenue	€47.53m
Cost of Revenue	€21.22m
Gross Profit	€26.31m
Other Expenses	€34.54m
Earnings	-€8.23m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.38
Gross Margin	55.35%
Net Profit Margin	-17.31%
Debt/Equity Ratio	0%

How did BNND perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/12/19 21:31
End of Day Share Price	2022/09/21 00:00
Earnings	2022/06/30
Annual Earnings	2021/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BRAIN Biotech AG is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Volker Bosse	Baader Helvea Equity Research
Thomas Meyer	Baader Helvea Equity Research
Laura Lopez Pineda	Baader Helvea Equity Research